Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.
2.

Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors.

Oza VB, Petrassi HM, Purkey HE, Kelly JW.

Bioorg Med Chem Lett. 1999 Jan 4;9(1):1-6.

PMID:
9990446
3.

Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis.

Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW.

J Med Chem. 2004 Jan 15;47(2):355-74.

PMID:
14711308
4.

Discovering transthyretin amyloid fibril inhibitors by limited screening.

Baures PW, Peterson SA, Kelly JW.

Bioorg Med Chem. 1998 Aug;6(8):1389-401.

PMID:
9784876
5.

Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors.

Oza VB, Smith C, Raman P, Koepf EK, Lashuel HA, Petrassi HM, Chiang KP, Powers ET, Sachettinni J, Kelly JW.

J Med Chem. 2002 Jan 17;45(2):321-32.

PMID:
11784137
6.
7.
8.

Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative.

Almeida MR, Macedo B, Cardoso I, Alves I, Valencia G, Arsequell G, Planas A, Saraiva MJ.

Biochem J. 2004 Jul 15;381(Pt 2):351-6.

9.

Modulation of the fibrillogenesis inhibition properties of two transthyretin ligands by halogenation.

Cotrina EY, Pinto M, Bosch L, Vilà M, Blasi D, Quintana J, Centeno NB, Arsequell G, Planas A, Valencia G.

J Med Chem. 2013 Nov 27;56(22):9110-21. doi: 10.1021/jm401061w. Epub 2013 Nov 7.

PMID:
24147937
10.
11.

Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.

Green NS, Palaninathan SK, Sacchettini JC, Kelly JW.

J Am Chem Soc. 2003 Nov 5;125(44):13404-14.

PMID:
14583036
12.

Synthesis and evaluation of transthyretin amyloidosis inhibitors containing carborane pharmacophores.

Julius RL, Farha OK, Chiang J, Perry LJ, Hawthorne MF.

Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):4808-13. Epub 2007 Mar 13.

13.

Inhibition of transthyretin amyloid fibril formation by 2,4-dinitrophenol through tetramer stabilization.

Raghu P, Reddy GB, Sivakumar B.

Arch Biochem Biophys. 2002 Apr 1;400(1):43-7.

PMID:
11913969
14.

Amyloid disease prevention by transthyretin native state complexation with carborane derivatives lacking cyclooxygenase inhibition.

Julius RL, Hawthorne MF.

Drug News Perspect. 2008 Jun;21(5):258-66. doi: 10.1358/dnp.2008.21.5.1219011. Review.

PMID:
18596990
15.

Kinetic assay for high-throughput screening of in vitro transthyretin amyloid fibrillogenesis inhibitors.

Dolado I, Nieto J, Saraiva MJ, Arsequell G, Valencia G, Planas A.

J Comb Chem. 2005 Mar-Apr;7(2):246-52.

PMID:
15762752
16.

Rational design of potent human transthyretin amyloid disease inhibitors.

Klabunde T, Petrassi HM, Oza VB, Raman P, Kelly JW, Sacchettini JC.

Nat Struct Biol. 2000 Apr;7(4):312-21. Erratum in: Nat Struct Biol 2000 May;7(5):431.

PMID:
10742177
17.

Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses.

Almeida MR, Gales L, Damas AM, Cardoso I, Saraiva MJ.

Curr Drug Targets CNS Neurol Disord. 2005 Oct;4(5):587-96. Review.

PMID:
16266291
18.

Drug competition for thyroxine binding to transthyretin (prealbumin): comparison with effects on thyroxine-binding globulin.

Munro SL, Lim CF, Hall JG, Barlow JW, Craik DJ, Topliss DJ, Stockigt JR.

J Clin Endocrinol Metab. 1989 Jun;68(6):1141-7.

PMID:
2498384
19.

Cell based screening of inhibitors of transthyretin aggregation.

Reixach N, Adamski-Werner SL, Kelly JW, Koziol J, Buxbaum JN.

Biochem Biophys Res Commun. 2006 Sep 29;348(3):889-97. Epub 2006 Jul 31.

PMID:
16904635
20.

Toward the discovery of functional transthyretin amyloid inhibitors: application of virtual screening methods.

Simões CJ, Mukherjee T, Brito RM, Jackson RM.

J Chem Inf Model. 2010 Oct 25;50(10):1806-20. doi: 10.1021/ci100250z.

PMID:
20883031

Supplemental Content

Support Center